angina with non-obstructive coronary arteries
Angina (or equivalent) with no stenosis ≥50% — up to half of patients sent for angiography; younger, fewer risk factors, more often women than obstructive CAD. A working diagnosis: coronary function testing finds a cause in 75–90% — microvascular dysfunction, microvascular or epicardial spasm, endothelial dysfunction, or a myocardial bridge, often more than one. A normal stress test does not exclude it; don’t label it non-cardiac until tested. Troponin rise with the same angiogram → MINOCA.
endotypes
| endotype | mechanism | definition on testing |
|---|---|---|
| coronary microvascular dysfunction (CMD) | structural remodelling, rarefaction, impaired endothelium-independent dilation | adenosine: CFR <2.0–2.5 and/or IMR ≥25 (hMR ≥2–2.5 by Doppler) |
| endothelial dysfunction | ↓ NO release → ACh constricts instead of dilating | ACh: epicardial constriction >0% to ≤90%, or coronary flow ↑ <50% |
| microvascular spasm | microvascular smooth-muscle hyperreactivity | ACh: usual pain + ischaemic ECG, no epicardial spasm |
| epicardial spasm (vasospastic angina) | large-artery hyperreactivity | ACh: >90% constriction + usual pain + ischaemic ECG |
| myocardial bridging | systolic compression of an intramyocardial segment; consider in all — angiography insensitive | IVUS halo / >10% compression; significant if dobutamine diastolic FFR, iFR or RFR ≤0.76 |
- CFR grey zone 2.0–2.4. Low CFR + high IMR = classic CMD, highest event risk; isolated low CFR (high resting flow) and isolated high IMR are distinct, less certain endotypes.
- CFR <2 by any modality → ↑ death and CV events, graded with severity.
- Epicardial spasm → ↑ MI and repeat angiography; microvascular spasm → recurrent angina. Overall prognosis of spasm favourable.
workup
- Non-invasive: PET myocardial blood flow reserve is the most accurate and prognostically validated (stress CMR perfusion and TTE Doppler LAD flow in select centres). AHA/ACC 2021 chest pain guideline: PET or stress CMR flow reserve 2a; invasive testing 2a if at least mild ischaemia on imaging.
- CCTA: non-invasive gold standard for myocardial bridge anatomy (length, depth); not physiology.
- Invasive coronary function testing (one sitting, LAD by default):
- adenosine + pressure/thermodilution wire → CFR, IMR
- ACh 20 µg slow (endothelial function) → 100 µg bolus (spasm); 200 µg optional (men, high suspicion); RCA ≤50 µg
- IVUS for bridging ± dobutamine physiology
- hold caffeine, nitrates, beta-blockers, CCBs, ACEi/ARB ≥24 h; avoid radial CCB “cocktail” (masks spasm); ≥6-lead ECG; nitroglycerin to reverse spasm
- Safety: major complications 0.5%, minor 4.4% (mostly transient AV block/bradycardia — pause ACh; AF usually self-limited); no deaths. No routine temporary pacing unless RCA tested.
vasospastic angina
| COVADIS criterion | detail |
|---|---|
| 1. nitrate-responsive angina (spontaneous) + ≥1 of | rest angina (night–early morning); morning ↓ exercise tolerance; hyperventilation-provoked; suppressed by CCB, not beta-blocker |
| 2. transient ischaemic ECG change (≥2 contiguous leads) | ST elevation or depression ≥0.1 mV, or new negative U waves |
| 3. coronary spasm | transient >90% constriction with angina + ischaemic ECG, spontaneous or provoked (ACh, ergonovine, hyperventilation) — all three, else equivocal |
- Definitive = 1 + (2 or 3). Suspected = 1 with 2 and 3 equivocal or unavailable. Prinzmetal (variant) angina = rest pain with transient ST elevation.
- Provocation strongly indicated: ACS without culprit, unexplained resuscitated arrest, syncope preceded by chest pain, recurrent rest angina after successful PCI, suspicious history unresponsive to empiric therapy. Contraindicated: emergent ACS, severe multivessel/left main disease, severe LV dysfunction, no suggestive symptoms.
- Invasive testing only — arrhythmia ~7%, no reported deaths; bedside non-invasive provocation has caused deaths.
- Risk factor: smoking (not diabetes or hypertension). Triggers: cocaine, 5-FU, allergen (Kounis), phaeochromocytoma.
treatment by endotype
Few adequately powered RCTs; sequential start with uptitration every few weeks, tracking symptoms (CCS class, Seattle Angina Questionnaire).
| endotype | first line | second / third line | notes |
|---|---|---|---|
| CMD | beta-blocker (vasodilating, e.g. nebivolol, may be preferable) + ACEi + statin | ranolazine (benefit if CFR <2.5), L-arginine, ivabradine; third: nicorandil (Health Canada SAP); trimetazidine (limited, conflicting data) | CCB benefit uncertain (diltiazem did not change CFR/IMR — EDIT-CMD); long-acting nitrate only if refractory |
| epicardial or microvascular spasm, endothelial dysfunction | CCB (DHP or non-DHP equally effective) + statin; SL nitroglycerin for episodes | DHP + non-DHP together; long-acting nitrate (tolerance — nitrate-free interval); cilostazol, cyproheptadine; nicorandil (CCS 2024); refractory spasm → stellate ganglion block | beta-blocker with caution (unopposed α → ↑ vasomotor tone); stop smoking, cocaine, trigger drugs (CCS 2024); diltiazem resolved epicardial spasm in 47% vs 6% (EDIT-CMD) |
| myocardial bridging | beta-blocker; CCB alternative | refractory → surgical unroofing | nitrates less effective (↑ systolic compression); stenting not advised (fracture, restenosis); CABG often fails (competitive flow) |
- All: exercise/cardiac rehab, weight loss, psychotherapy or meditation; TCA/SSRI if refractory (abnormal nociception); EECP or nerve stimulation for refractory angina; hormonal suppression if catamenial.
- Statin for all ANOCA (recommended broadly; improves endothelial function).
- Aspirin: no evidence of benefit in ANOCA, though commonly prescribed (observational link with more spasm) — give if atherosclerosis present.
- Undifferentiated ANOCA → WARRIOR (ASA + high-intensity statin + max ACEi/ARB vs usual care) ongoing.
- Women’s heart centres (BC, ON, QC, NS) for complex cases.
CorMicA (2018): ANOCA (n=151) → CFT found CMD 52%, spasm 17%, both 21%, none 11%; trial protocol stratified therapy to the result (CMD: ASA, statin, ACEi, beta-blocker → non-DHP CCB → DHP CCB/nicorandil/ranolazine; spasm: CCB + long-acting nitrate) ↑ angina and QoL at 1 year vs blinded usual care.
Prepared 2026-10-19. Not yet verified — check every number against the sources.